Clinical Trial Update: Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating neoadjuvant chemoradiation for borderline resectable pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: Seoul National University Hospital | Conditions: Pancreatic Cancer | Phase 2, Phase 3 | Status: COMPLETED